Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Melanoma treatment details. Immunotherapy. Memorial Sloan-Kettering Cancer Center, New York, NY, United States



Survival: 9.6 months
   
Toxicity Grade: 4
   
Treatments: Immunotherapy
   
Drugs:
Country: United States
   
City/State/Province: New York, NY
   
Hospital: Memorial Sloan-Kettering Cancer Center
   
Journal: Link
   
Date: 10/2013

Description:
Patients:
This study involved 39 metastatic uveal melanoma patients with a median age of 61 years, 59% of whom were male.

Treatment:
Patients were treated with the immune therapy agent ipilimumab, which is an antibody to the CTLA-4 protein and enhances the immune response against cancer cells.

Toxicities:
The most severe toxicities were of grade 4 and included grade 3-4 colitis (inflammation of the colon) and liver and pancreatic toxicities.

Results:
The median overall survival was 9.6 months.

Support:
Some of the authors have received funding from Bristol Myers Squibb (makers of ipilimumab).

Correspondence: Dr. Richard D. Carvajal; email: carvajar@mskcc.org

E-mail to a Friend Email Physician More Information